Celsis, a leader in rapid microbial testing systems for industry, has unveiled the Celsis Accel System for Pharma, a rapid microbial screening system for pharmaceutical manufacturing companies with midrange test volumes.

The Celsis Accel borrows the robustness and ease-of-use of the large capacity Celsis Advance II, packaged into a compact system specifically designed for midrange test volumes, said a statement.

Both systems allow compliance with regulatory guidance’s and offer full data analysis, report generation and remote user access, it said.

The Celsis Accel System for Pharma together with Celsis’ proprietary reagent technology, will decrease time necessary for quality control assessment of microbial contamination.

As a result, manufacturing cycle times will be shortened, quarantined inventory awaiting release will be reduced and working capital requirements will be diminished.

Meanwhile, Celsis worked with manufacturing facilities around the world, using its Financial Impact Assessment (FIA),  to evaluate the cost savings of implementing a Celsis system, said the statement.

Utilising company specific information including the value of products and the time and cost comparisons associated with the Celsis method, the FIA projects the five-year net present value (NPV) of a company’s investment in the Celsis system. It will typically in excess of $500,000 with even greater value for larger volume facilities or rapid sterility applications, it added.

Jay LeCoque, chief executive officer, said: “Testing requirements and regulatory oversight vary amongst the various industries served by Celsis. We saw the need for a smaller-scaled instrument platform that still provided the full system security, data analysis and reporting tools necessary for the pharmaceutical market.

“The Accel System for Pharma provides all the functionality of our high volume Advance II system but in a smaller throughput format.” - TradeArabia News Service